The FDA has accepted Sanofi and Regeneron’s application to expand Dupixent’s use, with a decision expected by April 2025.

Kennedy has been criticized for making false medical claims. He has also vowed to purge the U.S. Food and Drug Administration ...

EMA human medicine committee recommends approval of Sanofi’s Sarclisa to treat transplant-ineligible newly diagnosed multiple myeloma: Paris Saturday, November 16, 2024, 09:00 H ...

Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activity More than 300,000 people in the U.S. suffer from CSU that is inadequately controlled by ...

Health stocks slumped on Friday as Wall Street weighed the impact that prominent vaccine skeptic Robert F. Kennedy Jr. could ...

Manila Water Foundation Joins Erceflora Probiotics and Save the Children Philippines to Expand Hygiene and Water Access for ...

The resubmitted sBLA will include results from Study C, which evaluated biologic-naive patients with uncontrolled CSU on antihistamines.

London-listed GSK Plc and France’s Sanofi SA saw similar declines ... Centers for Medicare and Medicaid Services and the Food ...

Most European equity markets incurred in slight losses on Friday with pharma and technology stocks pacing losses.

FRANKFURT: European shares slipped on Friday, weighed down by disappointing earnings, concerns about the impact of ...

The decision makes it impossible to guess what might come next for the healthcare industry. Robert F. Kennedy Jr. is unlike ...

Europe's STOXX 600 fell on Friday, dragged by technology and healthcare stocks, keeping the index on track for its fourth ...